Related Experiment Video
Updated: Apr 27, 2026

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
Published on: March 1, 2024
Alternative polyadenylation is associated with lower expression of PABPN1 and poor prognosis in non-small cell lung
Junji Ichinose1, Kousuke Watanabe, Atsushi Sano
1Department of Thoracic Surgery, University of Tokyo Hospital, Tokyo, Japan.
Abstract:
Alternative polyadenylation (APA), which induces shortening of the 3'UTR, is emerging as an important phenomenon in gene regulation. APA is involved in development, cancer and cell proliferation. APA may lead to disruption of microRNA-mediated gene silencing in cancer cells via detachment of microRNA binding sites. We studied the correlation between the APA profile and the tumor aggressiveness in cases of lung cancer. We selected the top 10 genes showing significant 3'UTR shortening in lung cancer, using the package of the Bioconductor for probe-level analyses of expression microarrays. We established and evaluated the APA score by quantitative RT-PCR in 147 clinical specimens of non-small cell lung cancer and compared the results with the clinical outcomes and expression levels of APA-related genes, including PABPN1, CPEB1, E2F1 and proliferation markers (MKI67, TOP2A and MCM2). High APA scores were correlated with an advanced tumor stage and a poor prognosis (P < 0.001). Multivariate analysis identified the APA score as an independent prognostic factor (hazard ratio, 3.0; P = 0.03). Both lower expression of PABPN1 and higher expression of the proliferation markers were correlated with high APA scores and a poor prognosis, with suppression of PABPN1 exerting its influence independent of gain of the proliferation markers. Moreover, the APA score was correlated with the maximum standardized uptake value of the tumors on positron emission tomography (r = 0.53; P < 0.001). Our results indicate that the loss of PABPN1, a suppressor of APA, might promote tumor aggressiveness by releasing the cancer cells from microRNA-mediated gene regulation.
Insights
Alternative polyadenylation (APA) shortening of the 3' untranslated region (3'UTR) is linked to lung cancer aggressiveness. High APA scores correlate with advanced tumors and poor prognosis, identifying APA as a potential therapeutic target.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Alternative polyadenylation (APA) regulates gene expression by altering 3 UTR length.
- APA is implicated in cancer development and cell proliferation.
- APA-induced 3 UTR shortening may disrupt microRNA (miRNA)-mediated gene silencing in cancer.
Purpose of the Study:
- To investigate the correlation between APA profiles and tumor aggressiveness in lung cancer.
- To evaluate the prognostic value of an APA score in non-small cell lung cancer (NSCLC).
Main Methods:
- Analysis of top 10 genes with significant 3 UTR shortening in lung cancer using Bioconductor.
- Development and validation of an APA score via quantitative RT-PCR in 147 NSCLC specimens.
- Correlation analysis with clinical outcomes, gene expression (PABPN1, CPEB1, E2F1, MKI67, TOP2A, MCM2), and PET imaging findings.
Main Results:
- High APA scores significantly correlated with advanced tumor stage and poor prognosis (P < 0.001).
- The APA score was identified as an independent prognostic factor (HR, 3.0; P = 0.03).
- Low PABPN1 expression and high proliferation marker expression were associated with high APA scores and poor prognosis.
- APA score correlated with tumor metabolic activity on PET scans (r = 0.53; P < 0.001).
Conclusions:
- Loss of PABPN1, an APA suppressor, may promote lung cancer aggressiveness.
- APA-driven 3 UTR shortening potentially releases cancer cells from miRNA regulation.
- The APA score serves as a valuable prognostic biomarker in NSCLC.
Related Concept Videos
Abnormal Proliferation
RNA Splicing
lncRNA - Long Non-coding RNAs
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
